SCM
VKTX icon

Silverarc Capital Management’s Viking Therapeutics VKTX Stock Holding History

Silverarc Capital Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-20,000
Closed -$1.64M – 88
2024
Q1 		$1.64M Buy
+20,000
New +$890K 0.46% 54
2023
Q3 		– Sell
-258,595
Closed -$4.19M – 98
2023
Q2 		$4.19M Sell
258,595
-121,405
-32% -$2.54M 1.3% 27
2023
Q1 		$6.33M Buy
+380,000
New +$3.93M 2.61% 12

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Silverarc Capital Management's VKTX Position: Q2 2024 in Review

Silverarc Capital Management sold out of Viking Therapeutics (VKTX) in Q2 2024, closing a stake of 20,000 shares — an estimated $1.64M sold.

Silverarc Capital Management first reported a position in VKTX in Q1 2023 and held it in 3 quarters. The position peaked at $6.33M in Q1 2023. 387 funds tracked by Wall St. Rank hold VKTX as of Q2 2024.

  • Silverarc Capital Management reported no remaining Viking Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Silverarc Capital Management sold 20,000 Viking Therapeutics shares in Q2 2024, an estimated $1.64M.
  • Silverarc Capital Management first reported a position in Viking Therapeutics in Q1 2023 and held it in 3 quarters.
  • Silverarc Capital Management's Viking Therapeutics position peaked at $6.33M in Q1 2023.
  • 387 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2024.

Based on Silverarc Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.